BioCardia (NASDAQ:BCDA – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $25.00 target price on the stock.
BioCardia Stock Performance
BCDA stock opened at $1.85 on Thursday. The stock has a market capitalization of $3.93 million, a P/E ratio of -0.44 and a beta of 1.28. BioCardia has a one year low of $1.84 and a one year high of $14.40. The company has a 50 day moving average price of $2.58 and a two-hundred day moving average price of $3.33.
BioCardia (NASDAQ:BCDA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.78). Research analysts forecast that BioCardia will post -5.06 earnings per share for the current fiscal year.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Featured Stories
- Five stocks we like better than BioCardia
- The Significance of Brokerage Rankings in Stock Selection
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Quiet Period Expirations Explained
- Top-Performing Non-Leveraged ETFs This Year
- Which Wall Street Analysts are the Most Accurate?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
